title: Time to Reassess the Cancer Compendia for Off-label Drug Coverage in Oncology.
authors: Cancer Outcomes Research Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill.
authors: Angela K
authors: AK
authors: Green
authors: Cancer Outcomes Research Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill.
authors: William A
authors: WA
authors: Wood
authors: Cancer Outcomes Research Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill2Associate Editor, JAMA.
authors: Ethan M
authors: EM
authors: Basch
mesh_terms: D000068258:Bevacizumab / Q000627:therapeutic use; D014487:Centers for Medicare and Medicaid Services, U.S. / Q000592:standards*; D000068818:Cetuximab / Q000627:therapeutic use; D000069347:Erlotinib Hydrochloride / Q000627:therapeutic use*; D005569:Formularies as Topic / Q000592:standards*; D006801:Humans; D008495:Medical Oncology / Q000592:standards*; D009369:Neoplasms / Q000188:drug therapy*; D056687:Off-Label Use / Q000592:standards*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D012196:Review Literature as Topic; D014481:United States
chemical_list: D047428:Protein Kinase Inhibitors; D000068258:Bevacizumab; D000069347:Erlotinib Hydrochloride; D000068818:Cetuximab